PhD conferral Thomas Bergmeijer
Supervisor: Prof. dr. J.M. ten Berg
Co-supervisors: Dr. V.H.M. Deneer (Universiteit Utrecht), Dr. C.M. Hackeng (St.Antonius Ziekenhuis, Nieuwegein)
Keywords: antiplatelet treatment, CYP2C19, personalized medicine, pharmacogenetics
"Antiplatelet Treatment in Acute Myocardial Infarction"
In all patients who experienced a myocardial infarction, an antiplatelet drug will be prescribed, to prevent a new thrombotic event. While different antiplatelet drugs are available to choose from, the cardiologist will weigh the efficacy in preventing thrombotic events to the risk of drug side effects (e.g. risk for bleeding). When a genetic test for a CYP2C19 polymorphism is performed, it is possible to make a more optimal choice between the available antiplatelet drugs, in particular in preventing bleeding events. From a practical point of view, it was shown that the implementation of a genotype-guided treatment strategy for all patients admitted to the hospital for myocardial infarction is feasible.
Click here for the full dissertation.
Click here for the live stream.
Administrative Office
Also read
-
23 Sep10:00
PhD Defence Nivine Hanach
"Postpartum Depression in the UAE: Insights, Challenges, and Pathways to Support"
-
23 Sep13:00
PhD Defence Francesco Schianchi
"From v-ATPase to protein palmitoylation: Novel targets against lipid-induced cardiomyopathy"
-
23 Sep16:00
PhD Defence Khava Im Elievna Ibragimova
"Real-world treatment patterns and outcomes of patients with HER2+ advanced breast cancer"